Our MBC Life

View Original

The Project to End Post Partum Breast Cancer

See this content in the original post

If you’ve never heard of Postpartum Breast Cancer (PPBC) – well, you are not alone. This episode is a personal one for many on our podcast team – it is all about this little-known subset of breast cancer called Postpartum Breast Cancer (Postpartum means “following childbirth”) – how it happens, and why it creates a higher risk for metastatic spread and death. The doctors we interview here have proven that Postpartum Breast Cancer is a distinct category of breast cancer diagnosed in women within 10 years of having a baby. It affects 18,000 women in the US a year (that’s almost the same as ovarian cancer diagnoses in the US), and can happen across all subtypes, like hormone +/-, HER2+/-, or triple negative disease. *50%* of women diagnosed with breast cancer under age 45 in the US are actually diagnosed within a 10-year Postpartum window – 50%! Postpartum breast cancer also carries a higher risk for metastasis and death than breast cancer diagnosed outside this 10-year window. Now, Dr. Virginia Borges & Dr. Pepper Schedin are ready to move all their lab findings into the clinic by launching the first-in-human clinical trial to prevent Postpartum Breast Cancer – by giving healthy moms ibuprofen – yes, ibuprofen, for a brief period of time as they wean their babies from nursing. This is a groundbreaking clinical trial idea, with huge potential global impact, and they need the public’s help to make it happen.

To learn more, about this project and the fundraising efforts, you can visit The Project to End Post Partum Breast Cancer Fundraising Page.


Episode Notes

Citations:

The Lancet Oncology

Comment  Volume 22, Issue 6 p753-754 June 2021

The Definition of Pregnancy-Associated Breast Cancer (PABC) is Outdated and should no longer be used

Frédéric Amant, Virginia F Borges, et. al.

Summary:

“The definition of pregnancy-associated breast cancer (PABC) is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with cases diagnosed within 6 months to 1 year after the birth.1 Although pregnancy and the postpartum period are intertwined, evolving evidence supports considering breast cancer that occurs during pregnancy (PrBC) as a separate and distinct entity from breast cancer that occurs during the postpartum period (PPBC)—which, according to newer data, can extend to 5–10 years after the birth—because each type has unique biological attributes and prognosis.

JAMA Open Network

January 11, 2019

Association Between Postpartum Breast Cancer Diagnosis and Metastasis and the Clinical Features Underlying Risk

Erica T. Goddard, PhD1, et. al.

Key Points

Question  Is there an increased risk for metastasis of breast cancers that are diagnosed in young women post partum that extends beyond 5 years from the last childbirth, and what association do standard clinical prognostic factors have with metastatic risk in these young women when categorized by parity?

Findings  In a cohort study of 701 women 45 years or younger with breast cancer, those with stage I or II cancer diagnosed up to 10 years post partum had an increased risk for distant metastasis, with both estrogen receptor–positive and estrogen receptor–negative disease significantly affected.

Meaning  Postpartum status may be a prognostic indicator in young women with breast cancer and should be routinely identified, as up to 45% of women 45 years or younger with breast cancer fall into this category and could be at increased risk for metastasis.


Nature

October 16, 2020

npj Breast Cancer volume 6, Article number: 55 (2020)

Characterization of weaning-induced breast involution in women: implications for young women’s breast cancer

https://rdcu.be/dZWBf

Abstract

In rodents, weaning-induced mammary gland involution supports increased mammary tumor incidence, growth, and progression to metastasis. Further, the protumor attributes of gland involution are COX-2 dependent and mitigated by short-duration non-steroidal anti-inflammatory drugs (NSAIDs), suggesting a potential prevention strategy. However, the transition from lactation to postweaning breast involution has not been rigorously evaluated in healthy women. Here we queried breast biopsies from healthy women (n = 112) obtained at nulliparity, lactation, and multiple postweaning time points using quantitative immunohistochemistry. We found that mammary remodeling programs observed in rodents are mirrored in the human breast. Specifically, lactation associates with the expansion of large, secretory mammary lobules and weaning associates with lobule loss concurrent with epithelial cell death and stromal hallmarks of wound healing, including COX-2 upregulation. Altogether, our data demonstrate that weaning-induced breast involution occurs rapidly, concurrent with protumor-like attributes, and is a potential target for NSAID-based breast cancer prevention.


Meet the Guests of the Episode